SKIN SkinHealth Systems Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1818093 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.4%
TTM net income YoY-55.7%
TTM EPS YoY117.5%
Revenue 3-yr CAGR-10.3%
Net income 3-yr CAGR—
Margins
Gross margin67.2%
Operating margin2.4%
Net margin-6.3%
FCF margin7.9%
EBITDA margin3.2%
Returns
ROE-30.1%
ROA-4.1%
ROIC (approx.)7.1%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets85.7%
Debt / equity0.00x
Current ratio2.89x
Interest coverage0.27x
Cash quality & payout
Operating cash flow / net income-1.29x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $300.79M | $334.29M | $397.99M | $365.88M | $260.09M |
| Cost of revenue | $104.43M | $152.00M | $242.88M | $117.10M | $81.55M |
| Gross profit | $196.36M | $182.30M | $155.11M | $248.78M | $178.54M |
| R&D expense | $5.63M | $6.30M | $10.10M | $8.44M | $8.20M |
| SG&A expense | $117.95M | $125.46M | $131.43M | $106.10M | $98.69M |
| Operating income | -$20.80M | -$67.77M | -$130.92M | -$25.84M | -$39.93M |
| Interest expense | $19.33M | $10.41M | $13.65M | $13.39M | $11.78M |
| Pretax income | -$5.94M | -$29.55M | -$101.89M | $45.34M | -$380.64M |
| Income tax | $3.58M | -$452,000 | -$1.77M | $1.11M | -$1.88M |
| Net income | -$9.52M | -$29.10M | -$100.12M | $44.22M | -$378.76M |
| EBITDA | -$16.95M | -$57.83M | -$119.58M | -$18.68M | -$35.44M |
| EPS (basic) | -0.08 | -0.23 | -0.76 | 0.30 | -3.71 |
| EPS (diluted) | -0.16 | -0.36 | -0.76 | -0.23 | -3.71 |
| Weighted avg. shares (diluted) | 135.80M | 142.49M | 131.68M | 148.51M | 102.11M |
| Balance sheet | |||||
| Cash & equivalents | $232.67M | $370.06M | $523.02M | $568.20M | $901.89M |
| Receivables | $21.74M | $27.64M | $54.70M | $76.49M | $46.82M |
| Inventory | $48.01M | $69.11M | $91.32M | $109.66M | $35.26M |
| Current assets | $309.52M | $477.12M | $698.25M | $783.27M | $1.00B |
| PP&E, net | $2.54M | $5.98M | $14.23M | $18.18M | $16.18M |
| Goodwill | $126.62M | $123.50M | $125.82M | $124.59M | $123.69M |
| Intangibles | $35.76M | $47.51M | $62.12M | $46.39M | $56.01M |
| Total assets | $499.80M | $685.68M | $929.11M | $1.00B | $1.22B |
| Current liabilities | $186.28M | $68.15M | $115.01M | $71.71M | $76.44M |
| Long-term debt | — | $552.20M | — | — | — |
| Total debt | — | $552.20M | — | — | — |
| Total liabilities | $438.75M | $633.88M | $869.72M | $836.03M | $916.51M |
| Shareholders' equity | $61.06M | $51.80M | $59.39M | $167.05M | $298.03M |
| Net debt | — | $182.13M | — | — | — |
| Shares outstanding | 6.38M | 124.92M | 122.90M | 132.21M | 150.60M |
| Cash flow statement | |||||
| Operating cash flow | $37.48M | $16.13M | $21.75M | -$106.60M | -$28.36M |
| Capital expenditure | $303,000 | $756,000 | $3.83M | $10.85M | $11.20M |
| Free cash flow | $37.18M | $15.38M | $17.93M | -$117.45M | -$39.56M |
| Investing cash flow | -$5.16M | -$6.79M | -$31.51M | -$18.87M | -$37.73M |
| Financing cash flow | -$174.93M | -$158.34M | -$37.45M | -$205.24M | $959.03M |
| Depreciation & amortization | $3.85M | $9.94M | $11.33M | $7.16M | $4.49M |
| Stock-based compensation | $14.82M | $26.70M | $22.54M | $28.50M | $12.42M |
| Share buybacks | $0 | $0 | $30.16M | $160.00M | $0 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.